EWA
VIR icon

EverSource Wealth Advisors’s Vir Biotechnology VIR Stock Holding History

EverSource Wealth Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Sell
1,050
-494
-32% -$4.7K ﹤0.01% 2873
2026
Q1 		$13.8K Buy
1,544
+387
+33% +$3.08K ﹤0.01% 2741
2025
Q4 		$6.98K Buy
1,157
+50
+5% +$298 ﹤0.01% 2976
2025
Q3 		$6.32K Sell
1,107
-441
-28% -$2.25K ﹤0.01% 3044
2025
Q2 		$7.8K Buy
1,548
+1,237
+398% +$6.63K ﹤0.01% 2965
2025
Q1 		$2.02K Buy
311
+70
+29% +$622 ﹤0.01% 2927
2024
Q4 		$1.77K Buy
241
+71
+42% +$560 ﹤0.01% 2759
2024
Q3 		$1.27K Buy
170
+132
+347% +$1.15K ﹤0.01% 2663
2024
Q2 		$386 Buy
38
+3
+9% +$29 ﹤0.01% 2939
2024
Q1 		$296 Buy
+35
New +$356 ﹤0.01% 2778
2023
Q1 		– Sell
-20
Closed -$506 – 2543
2022
Q4 		$506 Buy
+20
New +$490 ﹤0.01% 2208

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EverSource Wealth Advisors's VIR Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Vir Biotechnology (VIR) stake by 32% in Q2 2026, selling an estimated $4.7K and leaving 1,050 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2873.

EverSource Wealth Advisors first reported a position in VIR in Q4 2022 and has held it in 11 quarters since. The position peaked at $13.8K in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • EverSource Wealth Advisors held 1,050 shares of Vir Biotechnology worth $10.7K as of Q2 2026.
  • EverSource Wealth Advisors sold 494 Vir Biotechnology shares in Q2 2026, an estimated $4.7K.
  • Vir Biotechnology made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2873 holding.
  • EverSource Wealth Advisors first reported a position in Vir Biotechnology in Q4 2022 and has held it in 11 quarters since.
  • EverSource Wealth Advisors's Vir Biotechnology position peaked at $13.8K in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.